You are here: Industry Insights > LIBERTY

News List

Myovant, Gedeon Richter’s uterine fibroids med Ryeqo bags EU approval pharmatimes
July 22, 2021
Myovant Sciences and Gedeon Richter have gained an approval from the European Commission (EC) for its uterine fibroids treatment Ryeqo, the company announced 20th.
FDA approves Pfizer, Myovant’s uterine fibroids drug Myfembree pharmatimes
May 27, 2021
The US Food and Drug Administration (FDA) has approved Pfizer and Myovant’s uterine fibroids drug Myfembree for the management of heavy menstrual bleeding.
Relugolix shows potential long-term benefit in women with uterine fibroids pharmatimes
March 26, 2021
Pfizer and Myovant Sciences have announced that relugolix combination therapy could have ‘potential benefit’ for the long-term treatment of women with uterine fibroids.
Myovant Sciences Announces Positive Phase 3 Results from LIBERTY 1 Study Evaluating Once Daily Relugolix Combination Therapy in Women with Uterine Fibroids drugs
May 20, 2019
Myovant Sciences Announces Positive Phase 3 Results from LIBERTY 1 Study Evaluating Once Daily Relugolix Combination Therapy in Women with Uterine Fibroids.